Gland Pharma Limited Bombay S.E.

Equities

GLAND

INE068V01023

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:48 2024-04-19 am EDT 5-day change 1st Jan Change
1,762 INR 0.00% Intraday chart for Gland Pharma Limited +0.83% -8.41%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Nicomac Machinery and RP Advisory Services Reportedly Likely to Sell 4.4% Stake in Gland Pharma via Block Deals CI
Gland Pharma Gets US FDA Approval for Eribulin Mesylate Injection MT
Gland Pharma Limited Receives Approval from the United States Food and Drug Administration for Eribulin Mesylate Injection 0.5 Mg/ML Single Dose Vial CI
Gland Pharma COO, Chief Technical Officer Step Down MT
Gland Pharma Limited Announces Change in Management CI
Gland Pharma Names New President of Phixen Subsidiary MT
Jefferies Adjusts Gland Pharma’s Price Target to INR2,400 From INR2,250, Keeps at Buy MT
Gland Pharma's Consolidated Profit Drops in Fiscal Q3 MT
Transcript : Gland Pharma Limited, Q3 2024 Earnings Call, Feb 14, 2024
Gland Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Indian shares set to open lower as hot US inflation spurs rate worries RE
Gland Pharma Gets Establishment Inspection Report from US FDA for Pashamylaram Unit MT
32,656,565 Equity Shares of Gland Pharma Limited are subject to a Lock-Up Agreement Ending on 18-NOV-2023. CI
Gland Pharma Gets US FDA's Tentative Approval for Generic Hypotension Drug MT
Gland Pharma Limited Receives Tentative Approval for Angiotensin II Injection CI
Abbott India's Q2 profit climbs on strong sales RE
Nomura Upgrades Gland Pharma to Neutral From Reduce, Adjusts Price Target to INR1,570 From INR1,157 MT
Gland Pharma Gets US FDA's EIR Report Closing Inspection of Visakhapatnam, India Unit MT
Jefferies Adjusts Gland Pharma's Price Target to INR1,800 From INR1,640, Keeps at Buy MT
Indian shares set to open marginally higher RE
Transcript : Gland Pharma Limited, Q2 2024 Earnings Call, Nov 06, 2023
India's Gland Pharma misses Q2 profit view on higher expenses RE
Gland Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Gland Pharma Gets EIR from US FDA After Inspection of Pashamylaram Facility in India MT
Gland Pharma Appoints CEO for Step-Down Subsidiary MT
Chart Gland Pharma Limited
More charts
Gland Pharma Limited is an India-based generic injectables manufacturer. The Company specializes in sterile injectables, oncology, and ophthalmic, with a specific focus on complex injectables, NCE-1s (New Chemical Entities), First-to-File products, and 505(b)(2) filings. The Company functions primarily on a business-to-business (B2B) model and has a record in pharmaceutical research and development, manufacturing, and marketing of complex injectables. The Company offers a range of delivery systems, including liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags, and drops. It is also in the process of including new delivery systems such as pens and cartridges into its product portfolio. Its key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. Its therapeutic products categories include Anti Malarials, Anti-Infectives, Anti-Neoplastics, Gynaecological, Hormones, and others.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
12
Last Close Price
1,764 INR
Average target price
1,845 INR
Spread / Average Target
+4.63%
Consensus
  1. Stock Market
  2. Equities
  3. GLAND Stock
  4. GLAND Stock
  5. News Gland Pharma Limited
  6. Gland Pharma : Nomura Starts Gland Pharma at Neutral With 2,637 Indian Rupees Price Target